Navigation Links
eResearchTechnology Reports First Quarter 2008 Results
Date:5/5/2008

.1 million, compared to $29.7 million for the

first quarter of 2007;

-- Bookings included seven new Thorough ECG study agreements valued at an

average of slightly greater than $1 million each;

-- The backlog was a record $151.4 million, a net increase of

$11.2 million from December 31, 2007;

-- The cancellation rate was an annualized 15.6% as compared to an

annualized cancellation rate of 15.0% in the first quarter of 2007.

"We are extremely pleased with the first quarter results where we saw record quarterly revenue, transactions, bookings and backlog for eRT," commented Dr. Michael McKelvey, President and CEO of eRT. "We continue to execute very well on our projects. The integration of the CCSS acquisition is proceeding on schedule, and we are meeting with clients to begin the transition process of individual studies. Our services revenue grew by 80.9%, driven by outstanding growth in our core cardiac safety business. Bookings were strong across all phases, but especially in Phase I and Phase III studies. The quarter again demonstrated the leverage in our business model as evidenced by expanding gross margins and net income growth."

The Company reported revenues of $33.7 million for the first quarter of 2008, an increase of 59.7% from $21.1 million in the first quarter of 2007. Net income was $5.7 million for the first quarter of 2008, an increase of 155.6% from $2.2 million for the first quarter of 2007. Diluted net income per share was $0.11 for the first quarter of 2008, up $0.07 from the $0.04 in the first quarter of 2007.

eRT ended the quarter with $48.9 million in cash, cash equivalents and investments, an increase of $2.0 million from $46.9 million at December 31, 2007. Operations generated $7.6 million, which was partially offset by payments to Covance under the terms of the CCSS acquisition.

"Our pipeline of new opportunities is strong, reflecting the continued emphasis on c
'/>"/>

SOURCE eResearchTechnology, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. eResearchTechnology to Present at the Deutsche Bank 33rd Annual Healthcare Conference on May 7th 2008
2. eResearchTechnology, Inc. to Announce 2008 First Quarter Results on May 5, 2008
3. eResearchTechnology, Inc. and nSpire Health, Inc. Form Alliance to Deliver Integrated Cardiac Safety and Pulmonary Clinical Trial Services
4. eResearchTechnology Reports Fourth Quarter and Full Year 2007 Results
5. eResearchTechnology, Inc. to Announce 2007 Fourth Quarter Results on February 26, 2008
6. eResearchTechnology to Present at the UBS Global Healthcare Services Conference 2008 on February 11th
7. eResearchTechnology to Present at the Thomas Weisel Healthcare Conference 2007 on September 5th
8. MannKind Corporation Reports First Quarter Financial Results
9. Verenium Reports Financial Results for the First Quarter 2008
10. ev3 Inc. Reports 2008 First Quarter Financial Results and Revised 2008 Guidance
11. United Therapeutics Reports First Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... 4, 2015   Tocagen Inc. , a ... from Tocagen,s ongoing investigational studies were presented at ... American Association of Neurological Surgeons (AANS)/Congress of Neurological ... 2015, in Washington, D.C. ... meeting with FDA and continues to advance towards ...
(Date:5/4/2015)... ALISO VIEJO, Calif. , May 4, 2015 /PRNewswire/ ... to eliminate preventable hospitalizations, has teamed with the ... effect of Sentrian technology on 1,000 patients with chronic ... nearly 13 million Americans and is the nation,s third ... plan members of CareMore Health System , a ...
(Date:5/1/2015)...  Northwest Biotherapeutics (NASDAQ: NWBO ) ("NW Bio"), ... for solid tumor cancers, announced today that the Company ... a $40 million investment from Woodford investment funds in ... million in NW Bio on November 19, 2014.  On ... the Company for a further $40 million investment in ...
(Date:5/1/2015)... - BioAmber Inc. (NYSE: BIOA ), an industrial ... priced an underwritten registered offering of 3,900,000 shares of ... share, and granted the underwriters in the offering a ... shares of its common stock. The gross proceeds to ... to close on May 6, 2015, subject to customary ...
Breaking Biology Technology:Tocagen Presents Updated Interim Survival Data from Ongoing Clinical Studies at American Association of Neurological Surgeons (AANS)/Congress of Neurological Surgeons (CNS) Section on Tumors 2Tocagen Presents Updated Interim Survival Data from Ongoing Clinical Studies at American Association of Neurological Surgeons (AANS)/Congress of Neurological Surgeons (CNS) Section on Tumors 3Tocagen Presents Updated Interim Survival Data from Ongoing Clinical Studies at American Association of Neurological Surgeons (AANS)/Congress of Neurological Surgeons (CNS) Section on Tumors 4Tocagen Presents Updated Interim Survival Data from Ongoing Clinical Studies at American Association of Neurological Surgeons (AANS)/Congress of Neurological Surgeons (CNS) Section on Tumors 5CareMore, Scripps Translational Science Institute, and Sentrian Launch Landmark Study of Remote Patient Monitoring for COPD Population 2CareMore, Scripps Translational Science Institute, and Sentrian Launch Landmark Study of Remote Patient Monitoring for COPD Population 3CareMore, Scripps Translational Science Institute, and Sentrian Launch Landmark Study of Remote Patient Monitoring for COPD Population 4CareMore, Scripps Translational Science Institute, and Sentrian Launch Landmark Study of Remote Patient Monitoring for COPD Population 5NW Bio Closes On $28.5 Million Second Tranche Of Woodford $40 Million Financing 2NW Bio Closes On $28.5 Million Second Tranche Of Woodford $40 Million Financing 3BioAmber Inc. Announces Pricing Of $35.1 Million Registered Offering 2BioAmber Inc. Announces Pricing Of $35.1 Million Registered Offering 3
... Oct. 1 /PRNewswire-FirstCall/ - Medicago U.S.A. Inc., a ... a biotechnology company focused on developing highly effective ... and Virus-Like Particles (VLPs), today announced that company ... and U.S. Congressman David Price (D-NC), are holding ...
... Market Presence in PRC Healthcare Laboratory Market -- re> SINGAPORE and HONG KONG, Sept. 30 /PRNewswire-Asia/ -- ... ... (typeof(lpUnit)==,undefined,) var lpUnit=,PRN,; --> ... function(data) { var s = ,; var first_result; // Results are keyed by longUrl, so we need ...
... VANCOUVER, Sept. 30 /PRNewswire-FirstCall/ - Teva Pharmaceuticals Industries Ltd. ... (NASDAQ: OGXI ) announced today the initiation ... (also known as OGX-011/TV-1011) as first line therapy for ... trial is the second of three Phase 3 trials ...
Cached Biology Technology:Medicago holds official groundbreaking ceremony for its U.S. commercial grade vaccine facility 2Medicago holds official groundbreaking ceremony for its U.S. commercial grade vaccine facility 3Techcomp to Expand Market Presence in PRC Healthcare Laboratory Market 2Techcomp to Expand Market Presence in PRC Healthcare Laboratory Market 3Techcomp to Expand Market Presence in PRC Healthcare Laboratory Market 4Techcomp to Expand Market Presence in PRC Healthcare Laboratory Market 5Techcomp to Expand Market Presence in PRC Healthcare Laboratory Market 6Techcomp to Expand Market Presence in PRC Healthcare Laboratory Market 7Techcomp to Expand Market Presence in PRC Healthcare Laboratory Market 8TEVA AND ONCOGENEX ANNOUNCE INITIATION OF SECOND PHASE 3 TRIAL OF CUSTIRSEN IN MEN WITH METASTATIC PROSTATE CANCER 2TEVA AND ONCOGENEX ANNOUNCE INITIATION OF SECOND PHASE 3 TRIAL OF CUSTIRSEN IN MEN WITH METASTATIC PROSTATE CANCER 3TEVA AND ONCOGENEX ANNOUNCE INITIATION OF SECOND PHASE 3 TRIAL OF CUSTIRSEN IN MEN WITH METASTATIC PROSTATE CANCER 4TEVA AND ONCOGENEX ANNOUNCE INITIATION OF SECOND PHASE 3 TRIAL OF CUSTIRSEN IN MEN WITH METASTATIC PROSTATE CANCER 5TEVA AND ONCOGENEX ANNOUNCE INITIATION OF SECOND PHASE 3 TRIAL OF CUSTIRSEN IN MEN WITH METASTATIC PROSTATE CANCER 6
(Date:3/24/2015)... NexID Biometrics LLC, whose spoof-mitigation technology boosts protection ... beginning of shipments of version 2.0 of its industry ... in Potsdam, N.Y. , is making ... here today at the Walter E. Washington Convention Center. ... boosts the accuracy rate range to 96.5 to 99.5 ...
(Date:3/23/2015)... , March 23, 2015   HOYOS Labs , ... company, today announced that the Company will demonstrate multiple ... enterprise and consumers at Connect:ID on March 23 through ... HOYOS Labs will highlight the IEEE Biometric Open Protocol ... ; and enterprise access control system. BOPS was invented ...
(Date:3/20/2015)... , Mar. 20, 2015 Research and ... the addition of the "India Sensors Market ... offering. The sensor market is projected ... 2020 Consumer electronics, automotive, industrial and ... sensors in the country. In addition, adoption of ...
Breaking Biology News(10 mins):NexID Begins Shipments Of Version 2.0 Fake-Finger-Detection Solution 2HOYOS Labs to Showcase Host of Biometrics Technologies at Connect:ID in Washington, D.C. 2HOYOS Labs to Showcase Host of Biometrics Technologies at Connect:ID in Washington, D.C. 3India Sensors Market Forecast and Opportunities 2020 - STMicroelectronics held the largest share in 2014 2India Sensors Market Forecast and Opportunities 2020 - STMicroelectronics held the largest share in 2014 3
... Charles Drew University of Medicine and Science and UC ... and their parents as part of a comprehensive initiative ... Karen Cheng, CDU psychiatry and human behavior ... a $480,000 grant from the Robert Wood Johnson Foundation ...
... This release is available in Spanish . ... and gaining nutrition savvyplus physical fitness skillsare emerging from ... For example, investigators Craig A. Johnston, John P. ... upon one of their earlier studies in which many ...
... scientists in the United Kingdom and the Netherlands ... become progressively more resistant to antibiotics over the ... apparent more stringent rules on use of antibiotics ... technology that broadly improves water quality in surrounding ...
Cached Biology News:Charles Drew University, UC Irvine awarded $480,000 grant for research low birth weight infants 2Charles Drew University, UC Irvine awarded $480,000 grant for research low birth weight infants 3Kids lose pounds, gain fitness in Houston study 2
... GX-1000 3-D Shaker , ,Product Information ... of the GyroTwister GX-1000 is extremely efficient, ... general mixing as well as staining gels, ... continuously adjustable across a broad range. A ...
...
... Radiolabeled Ligands\n\nReceptor-related research has long been enabled ... ligands selected to keep pace with new ... products and services for receptor research and ... If you do not find exactly what ...
...
Biology Products: